Publikationen von 2005 bis 2009

  • Handrick R, Ganswindt U, Faltin H, Goecke B, Daniel PT, Budach W, Belka C, Jendrossek V. Combined action of celecoxib and ionizing radiation in prostate cancer cells is independent of proapoptotic Bax. Radiother Oncol 90, 413-421 (2009).
  • Niyazi M, Marini P, Daniel PT, Humphreys R, Jendrossek V, Belka C. Efficacy of a triple treatment with irradiation, agonistic TRAIL receptor antibodies and EGFR blockade. Strahlenther Onkol 185, 8-18 (2009).
  • Rudner J, Mueller A-C, Matzner N, Huber S, Handrick R, Belka C, Jendrossek V. The additional loss of Bak and not the lack of the protein tyrosine kinase p56/Lck in one JCaM1.6 subclone caused pronouced apoptosis resistants in response to stimuli of the intrinsic pathway. Apoptosis 14(5):711-20 (2009).
  • Niyazi M, Marini P, Daniel PT, Humphreys R, Jendrossek V, Belka C. Efficacy of a triple therapies including ionising radiation, agonistic TRAIL antibodies and cisplatin. Oncol Rep 21:1455-1460 (2009).
  • Marini P, Budach W, Niyazi M, Junginger D, Stickl S, Jendrossek V, Belka C. Combination of pro-apoptotic TRAIL-receptor antibodies with ionizing radiation strongly increases long term tumor control under ambient and hypoxic conditions. Int J Radiat Oncol Biol Phys 75:198-202 (2009).
  • Henke G, Lindner LH, Vogeser M, Eibl H, Wörner J, Müller AC, Bamberg M, Wachholz K, Belka C, Jendrossek V. Pharmacokinetics and biodistribution of Erufosine in nude mice - implications for combination with radiotherapy. Radiation Oncology 4:46 (2009).
  • Grandoch M, Rose A, ter Braak M, Jendrossek V, Rübben H, Fischer JW, Schmidt M, Weber AA. Epac inhibits migration and proliferation of human prostate carcinoma cells. Br J Cancer 101(12):2038-42. (2009).
  • Chometon G, Jendrossek V: Targeting the tumour stroma to increase efficacy of chemo- and radiotherapy. Clin Transl Oncol 11, 75-81 (2009). (Review).
  • Jendrossek V, Henkel M, Hennenlotter J, Vogel U, Ganswindt U, Müller I, Handrick R, Kuczyk M, Stenzl A, Belka C. Analysis of complex PKB/Akt signaling pathways in human prostate cancer samples Brit J Urol 102, 371-382 (2008).
  • Jendrossek V. Radioprotektion durch TOLL-like Rezeptor-5-vermittelte Aktivierung von NF-kB. Strahlenther Onkol 184;612-614 (2008). Kommentar.
  • Müller AC, Handrick R, Elsaesser SJ, Rudner J, Henke G, Ganswindt U, Belka C, Jendrossek V. Importance of Bak for celecoxib-induced apoptosis. Biochem Pharmacol 76(9), 1082-1096 (2008).
  • Brand V, Koka S, Lang C, Jendrossek V, Huber SM, Gulbins E, Lang F. Influence of amitriptyline on eryptosis, parasitemia and survival of Plasmodium berghei- infected mice). Cell Physiol Biochem 22(5-6), 405-412 (2008).
  • Li M, Jendrossek, V, Belka: The role of PDGF in cancer research. Radiation Oncology 2, 5 (2007).
  • Rübel A, Handrick R, Lindner LH, Steiger M, Eibl H, Budach W, Belka C, Jendrossek V. The membrane targeted apoptosis modulators erucylphospho­choline and erucylphosphohomocholine increase the radiation response of human glioblastoma cell lines in vitro. Radiation Oncology, 1, 6 (2006).
  • Marini P, Denzinger S, Schiller D, Kauder S, Welz S, Humphreys R, Daniel PT, Jendrossek V, Budach W, Belka C. Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth delay in vivo. Oncogene 25, 5145-5154 (2006).
  • Ganswindt U, Budach W, Jendrossek V, Becker G, Bamberg M, Belka C. Combination of celecoxib with percutaneous radiotherapy in patients with localised prostate cancer. Radiation Oncology 1, 9 (2006).
  • Heinzelmann F, Jendrossek V, Lauber K, Nowak K, Eldh T, Boras R, Handrick R, Henkel M, Martin C, Uhlig S, Köhler D, Eltzschig HK, Wehrmann M, Budach W, Belka C. Irradiation induced pneumonitis is mediated by the CD95/CD95-ligand system. J Nat Canc Inst 98, 1248-1251 (2006).
  • Handrick R, Rübel A, Faltin H, Eibl H, Belka C, Jendrossek V. Increased cytotoxicity of ionizing radiation in combination with membrane-targeted apoptosis modulators involves downregulation of Proteinkinase B/Akt-mediated survival-signalling. Radiother Oncol 80, 199-206 (2006).
  • Habermehl D, Kammerer B, Handrick R, Eldh T, Gruber C. Cordes N, Daniel PT, Plasswilm L, Bamberg M, Belka C, Jendrossek V. Proapoptotic activity of Ukrain is based on Chelidonium majus L. alkaloids and mediated via a mitochondrial death pathway. BMC Cancer 6(1), 14 (2006).
  • Rudner J, Jendrossek V, Lauber K, Daniel PT, Wesselborg S, Belka C. Type I and type II reactions in TRAIL-induced apoptosis - results from dose response studies. Oncogene 24, 130-140 (2005).
  • Marini P, Schmid A, Jendrossek V, Faltin H, Daniel PT, Budach W, Belka C. Irradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosis. BMC Cancer 5(1), 5 (2005).
  • Lang PA, Kempe DS, Tanneur V, Eisele K, Klarl BA, Myssina S, Jendrossek V, Ishii S, Shimizu T, Waidmann M, Hessler G, Huber SM, Lang F, Wieder T. Stimulation of erythrocyte ceramide formation by platelet activating factor. J Cell Sci. 118(Pt 6), 1233-1243 (2005).
  • Weinmann M, Belka C, Guner D, Goecke B, Muller I, Bamberg M, Jendrossek V. Array-based comparative gene expression analysis of tumor cells with increased apoptosis resistance after hypoxic selection. Oncogene. 24(38), 5914-5922 (2005).
  • Handrick R, Rudner J. Müller I, Eibl H, Belka C, Jendrossek V. Bcl-2-mediated inhibition of erucylphosphocholine-induced apoptosis depends on its subcellular localisation. Biochem Pharmacol. 70, 837-850 (2005).
  • Kornhuber J, Medlin A, Bleich S, Jendrossek V, Henkel AW, Wiltfang J, Gulbins E. High activity of acid sphingomyelinase in major depression.J Neural Transm. 112, 1583-1590 (2005).

Nach oben